Skip to main content
. 2023 Jul 12;15(14):3592. doi: 10.3390/cancers15143592

Figure 2.

Figure 2

(A): Percentages of cells (CD3−CD56+ NK, CD3+CD56− T lymphocytes, CD19+ B lymphocytes, and CD14+ monocytes) before and after ICI therapy. (B): Histogram represents % of cells at baseline evaluation (T0). Results are expressed as mean ± SD, * p < 0.05, ** p < 0.01.